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1.55 (95% CI: 1.00, 2.42); p = 0.05] remained associated with rapid progression after salvage RT after
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Running title: Importance of central pathology review  
 
ABSTRACT  
Objectives: To conduct a central pathology review within a randomized clinical trial on 
salvage radiation therapy (RT) in the presence of biochemical recurrence after prostatectomy 
to assess whether this results in shifts of histopathological prognostic factors such as the 
Gleason Score.  
Patients and Methods: A total of 350 patients were randomized and specimens of 279 (80%) 
of the patients were centrally reviewed by a dedicated genitourinary pathologist.  
The Gleason Score, tumor classification and resection margin status were reassessed and 
compared with the local pathology reports. Agreement was assessed using contingency 
tables and Cohen’s Kappa. Additionally, the association between other histopathological 
features (e.g. largest diameter of carcinoma) with rapid biochemical progression (up to 6 
months after salvage RT) was investigated. 
Results: There was good concordance between central pathology review and local 
pathologists for seminal vesicle invasion [pT3b: 91%; k=0.95 (95% CI 0.89, 1.00)], for 
extraprostatic extension [pT3a/b: 94%; k=0.82 (95% CI 0.75, 0.89)], and for positive surgical 
margin status [87%; k=0.7 (95% CI 0.62, 0.79)]. Agreement was lower for Gleason score 
[78%; k=0.61 (95% CI 0.52, 0.70)]. The median largest diameter of carcinoma was 16 mm 
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(range, 3–38 mm). A total of 49 patients (18%) experienced rapid biochemical progression 
after salvage RT. Largest diameter of carcinoma [odds ratio (OR): 2.04 (95% Confidence 
interval (CI): 1.30, 3.20); p = 0.002], resection margin status [OR: 0.36 (95% CI: 0.18, 0.72); 
p = 0.004] and Gleason score [OR: 1.55 (95% CI: 1.00, 2.42); p = 0.05] remained associated 
with rapid progression after salvage RT after backward selection. 
 
Conclusion: The results of the central pathology analyses reveal concordant results for 
seminal vesicle invasion, extraprostatic extension, positive surgical margin but lower 
agreement for Gleason Score. Largest diameter of carcinoma was found to be a potential 
prognostic factor for rapid biochemical progression after salvage RT. 
 
INTRODUCTION 
Patients with biochemical recurrence after prostatectomy without evidence of distant 
metastatic disease commonly undergo early salvage radiation therapy (RT) of the prostate 
bed as their major curative treatment approach. There are several established pathological 
features such as the Gleason Score, tumor classification and resection margin status which 
can serve as prognostic factors for the outcome after salvage RT and thus must be assessed 
in a standardized fashion (1, 2). However, it has been previously described that these factors 
could significantly vary when being assessed by dedicated genitourinary pathologist in a 
central pathology review (3, 4, 5). This may influence the outcome analyses of clinical trials 
and therefore the use of central pathology reviews is recommended (6). 
Moreover, once centrally reviewed, additional histopathological features can uniformly be 
assessed which can potentially serve as additional prognostic factors.  
It has been described that around one fifth of patients experience rapid biochemical 
progression after RT and these patients may harbor micrometastatic or radioresistant 
disease and may require a more tailored treatment approach (7). Thus it it appears to be 
important to search for clinical and histopathological predictors for rapid biochemical 
progression. 
We describe here the differences between the central and local pathology results for patients 
treated within our clinical trial on salvage RT and analyze the association of several 
histopathological features and rapid biochemical progression after salvage RT. 
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PATIENTS AND METHODS 
Trial design and conduct 
Between 02/2011 and 04/2014, 350 patients were enrolled in an international phase III 
randomized controlled trial (Swiss Group for Clinical Cancer Research, SAKK 09/10) on 
dose-intensified (70 Gy over 7 weeks) versus standard-dose (64 Gy over 6.4 weeks) salvage 
RT in biochemically relapsed prostate cancer patients without macroscopic disease as 
previously described (8). The trial was conducted in 28 hospitals (Switzerland: 14, Germany: 
11, Belgium: 3). Patients were eligible if they had evidence of biochemical recurrence (two 
consecutive rises in prostate-specific antigen (PSA) with final PSA >0.1 ng/ml, or 3 
consecutive rises) and a PSA at randomization of ≤2 ng/ml. The trial was registered under 
ClinicalTrials.gov identifier NCT01272050. The full list of inclusion and exclusion criteria can 
be found at ClinicalTrials.gov web site.  
Radical prostatectomy was performed at least 12 weeks before randomization and was not 
part of this trial. All prostatectomy techniques were permitted. Within 16 weeks prior to 
randomization, either a MRI (recommended) or a multislice CT of the abdomen and pelvis 
was mandatory to exclude macroscopic local recurrence or lymph node metastases.  
The primary endpoint of the trial was freedom from biochemical progression. The trial was 
designed as a two-arm phase III trial, assuming a median freedom from biochemical 
progression ≤ 3.8 years for the null hypothesis, and ≥ 5.8 years for the alternative hypothesis 
(i.e. absolute difference = 2 years, hazard ratio = 0.6526). The one-sided type I error was 5% 
and the power 80%. The number of events required for primary analysis was 139, and the 
sample size 350 patients. 
 
Central pathology Review 
The pathological review was performed by a single pathologist with experience in urogenital 
pathology (VG) and included the examination of all slides of the radical prostatectomy 
specimen.  
Central pathology review was defined as mandatory in the trial protocol. Before centers were 
opened for accrual a pathology agreement form had to be signed by the main local 
pathologists stating that its institution is willing to submit slides of the prostatectomy 
specimen to the central pathology review which was conducted at the department of 
pathology of the University of Bern, Switzerland. Local pathologists were required to send in 
hematoxylin-eosin (HE) stained slides pseudonymized together with a report of the local 
pathology assessment. Gleason Score, tumor classification, presence of extraprostatic 
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extension, invasion of seminal vesicles, and surgery margin status were recorded. If 
extracapsular extension was present, its extent was assessed according to Wheeler criteria 
(focal: neoplastic glands outside the prostate <1 high power field, hpf on ≤2 separat sections 
neoplastic glands outside the prostate, established: anything more extensive than focal) and 
sidedness were recorded (anterior, apical, base, posterolateral) (9). Extraprostatic extension 
was defined as involvement off fat and/or loos connective tissue in plane of fat or beyond, 
involvement of perienural space in large neurovascular bundles, bulging tumor beyond the 
normal contours of the prostate gland, sometimes with desmoplastic stromal reaction (9). 
Positive surgical margin (PSM) status was recorded in case of the presence of tumor cells 
within the inked margin. For PSM, apical and non-apical (designated as anterior, base, 
posterolateral or seminal vesicles) involvement was distinguished.  
The following local pathology features were obtained by case report form assessment and 
thus available in the database: tumor classification, Gleason pattern and Score, PSM status. 
Central pathology review was carried out according to defined standards (3) and the Gleason 
Score was assigned according to the 2005 International Society of Urological Pathology 
(ISUP) consensus (10). Additionally, a new grading system was used to re-classify patients 
and to compare changes between local and central pathology assessment (11). For tumor 
classification the 2009 American Joint Committee on Cancer Staging System was used. 
Furthermore, the presence of lymphovascular and perineural invasion was assessed, as well 
as the localization of the largest lesion, the Gleason score within the largest lesion and the 
largest diameter of carcinoma. These variables were not available for the local pathology 
assessments and could thus not be compared. 
A total of 279 (80% of the 350 trial participants) of prostatectomy specimens provided by 
local pathologists of 23 centers were reviewed. The remaining samples could not be 
analyzed because they were not provided by the local pathologists despite multiple 
reminders. 
 
Statistical analysis 
All patients who completed at least one salvage RT session and whose prostatectomy 
specimens were reviewed by the central pathologist were included in this analysis.   
The assessments from local and review pathology were compared using contingency tables 
and Cohen’s Kappa.  
PSA doubling time after prostatectomy was calculated from the natural log of 2 divided by the 
slope of the relationship between the time of PSA measurement and the log of PSA using 
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linear regression for each patient using all PSA measurements from prostatectomy until 
randomization. 
The PSA values during the first 6 months after completion of salvage RT were used to 
assess PSA change. Patients were discriminated between rising PSA at any time during the 
first 6 months after completion of salvage RT (defined as rapid biochemical progression) and 
PSA response or stable PSA during the first 6 months after completion of salvage RT. 
Histopathological features were compared between the two patient groups using Wilcoxon 
rank sum tests for continuous variables and Fisher’s exact tests for categorical variables. 
Furthermore, univariable and multiple logistic regression models with backward selection 
were applied to investigate the influence of preselected histopathological features and clinical 
parameters on rapid biochemical progression. Before applying the models pairwise 
correlations between the variables were investigated descriptively to avoid multicollinearity. 
Two-tailed tests with significance level 0.05 were used for all analyses. As no adjustment for 
multiple testing for these analyses was made, they were exploratory and hypothesis 
generating. All analyses were performed using SAS 9.4 (SAS Institute) and R 3.2.4 
(http://www.r-project.org). 
RESULTS 
227 (81%) of patients experienced a PSA reduction (n=225) or stable PSA values (n=2) in 
their first two follow-up visits (3 and 6 months after completion of RT) as compared to the 
pre-salvage RT value. The remaining 49 patients (18%) experienced rising PSA and were 
considered as having rapid biochemical progression. Three patients (1%) had missing PSA 
values after RT.  
The median PSA prior to salvage RT was 0.3 ng/mL (range, 0.0 – 1.4 ng/mL) and the 
median PSA doubling time prior to salvage RT was 7.6 months (range -155.3 − 95.6) and the 
PSA velocity prior to salvage RT was 0.1 ng/mL/year (range -0.0 − 2.6). 
 
Level of agreement between review and local pathology  
There was good concordance between central review and local pathologists regarding 
seminal vesicle invasion [pT3b: 91%; k = 0.95 (95% CI 0.89, 1.00)], PSM status [87%; k = 
0.7 (95% CI 0.62, 0.79)], and for extraprostatic extension [pT3a/b: 94%; k = 0.82 (95% CI 
0.75, 0.89)].  
Among the 115 patients with extraprostatic extension according to local pathology 108 (94%) 
were confirmed by central pathology. Of the 164 patients being considered pT2 according to 
local pathology 146 (89%) were confirmed as pT2 but 18 (11%) were identified to be pT3 
according to central pathology review. Thus the proportion of patients with pT3 increased 
from 41 to 45% after the central pathology review (Table 1). 
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Of the 152 patients with negative surgical margins according to local pathology, 124 (82%) 
were confirmed as R0 and 26 (17%) were considered as PSM after central pathology review. 
For three patients surgical margin status was not available from the central review.  Of the 
127 patients with PSM according to local pathology, 111 (87%) were confirmed as PSM but 
15 (12%) were considered R0. As a result the rate of patients being considered as PSM 
increased to 49% (pathologic review: 137 of 279 specimens) compared with 45% (local 
pathologists: 127 of 279).  
Agreement was lower for Gleason score (78%; k=0.61 (95% CI 0.52, 0.70)), whereby the 
pathology review resulted in a shift of the score from lower as well as higher levels to 
Gleason 7 (Table 2). Interestingly, the agreement was higher for the primary Gleason pattern 
(k=0.61) than for the secondary Gleason pattern k=0.41) (Table 2). When comparing the new 
grading system, a similar agreement between local pathology and central review was found 
(65%; k=0.65 (95% CI 0.58, 0.71)) (data not shown). 
 
 
 
Assessment of additional histopathological features 
A total of 244 patients (88%) were found to be positive for perineural invasion and a total of 
33 patients (12%) were positive for lymphovascular invasion. The median largest diameter of 
carcinoma was 16 mm (range, 3 – 38 mm). Continuous additional histopathological variables 
were summarized in Table 3.  
 
Association between clinical and histopathological features and rapid biochemical 
progression 
The results of the comparison of histopathological features between patients with rapid 
biochemical progression and patients with stable PSA or PSA response are shown in Table 
4. After applying multivariable logistic regression models with backward selection, largest 
diameter of carcinoma [odds ratio (OR): 2.04 (95% Confidence interval (CI): 1.30, 3.20); p = 
0.002], resection margin status [OR: 0.36 (95% CI: 0.18, 0.72); p = 0.004] and Gleason score 
[OR: 1.55 (95% CI: 1.00, 2.42); p = 0.05] remained significantly associated with rapid 
biochemical progression after salvage RT. In a next step these three variables as well as 
clinical variables were included in multiple logistic regression models. Again largest diameter, 
resection margin status and Gleason score remained significantly associated with rapid 
biochemical progression after salvage RT after backward selection (Table 5). 
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DISCUSSION 
The results of the present central pathology review analysis confirmed a good concordance 
for major histopathological prognostic factors such as seminal vesicle invasion, extraprostatic 
extension, positive surgery margin but lower agreement for Gleason Score. Additionally, we 
could identify the diameter of largest carcinoma as a potential prognostic factor for rapid 
biochemical progression after salvage RT.  
Van der Kwast described the results of a central pathology review of 552 radical 
prostatectomy specimens. They found a high concordance rate for seminal vesicle invasion 
(94%, κ=0.83) but the agreement was much less for extraprostatic extension (57.5%, κ=0.33) 
and for surgical margin status (69.4%, κ=0.45) (3).  
Bottke et al. found similar results with a good concordance for seminal vesicle invasion (91%; 
k = 0.76), and the agreement for extraprostatic extension (75%; k = 0.74) and surgical 
margin status (84%; k = 0.65) being lower. Again, concordance was much less for Gleason 
score (47%; k = 0.42) (5).  
In an analysis of 2015 radical prostatectomy specimen others have also described a good 
concordance for seminal vesicle invasion (97.6%; k = 0.82), and the agreement for 
extraprostatic extension (82.5%; k = 0.59) and surgical margin status (87.5%; k = 0.73) being 
lower and Gleason Score being less concordant with 54.8% (4).  
The concordance rates of our study for seminal vesicle invasion, extraprostatic extension 
and for PSM status and Gleason score compared well with the results of the three other 
mentioned studies (3-5).  
The difference between the local and central review regarding Gleason score is not 
surprising. The application of the Gleason grading system changed repeatedly over time and 
particularly the consensus report by the ISUP 2005 (10), which was used for central 
pathology review, resulted in a distinct shift of Gleason grades. Since the prostatectomy 
specimens included in the present study date from different years back to 1998, the 
differences in Gleason grading can be well explained by these changes in grading practice. 
Regarding resection margins and extraprostatic extension there is missing standardization 
and variability between different institutions. This issue was addressed and changed only in 
the ISUP working group reports on handling and staging of radical prostatectomy specimens 
(9).  
However, the central pathology review relevantly shifted the assessment of important 
prognostic factors and should therefore routinely be conducted within multicenter clinical 
trials.  
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Specifically, the higher total rate of patients being considered as pT3 (45% instead of 41%) 
and as having a PSM (49% instead of 45%) after central pathology review would have led to 
more patients undergoing adjuvant RT after radical prostatectomy. On the other hand the 
shifts recognized by the central pathology review may influence the patients prognosis after 
RT as provided by a contemporary validated nomogram and are thus of interest (12). 
Beyond these standard histopathological features as mentioned above there weren’t other 
histopathological features which were routinely assessed and thus in today´s clinical practice 
no other pathological variables are being considered as major prognostic factors (2). 
We took advantage of the possibility to uniformly assess several other histopathological 
features which could potentially serve as future prognostic factors. We then divided the 
patients in men with PSA response or stable PSA and men with rapid biochemical 
progression in the early phase of follow-up after salvage RT and identified the largest 
diameter of carcinoma to be independently associated with rising PSA after salvage RT. 
Patients with rapid biochemical progression likely harbor micrometastatic disease or 
radioresistant disease and may benefit from more tailored treatment e.g. addition of 
androgen deprivation therapy (ADT) (7). The prognostic significance of largest diameter of 
carcinoma has been described controversially, some have described it as independent 
prognostic factor (13) others as less important (14). Once our trial will have mature 
biochemical control results we will repeat the analysis to identify prognostic factors and might 
be able to include some of the histopathological features in a Nomogram (2). No relevant 
differences in largest diameter of carcinoma were observed between the two treatment arms. 
Others have described genomic classifier to be able to predict metastases among men 
receiving salvage RT for biochemically recurrent prostate cancer (15). A combination of 
histopathological features as assessed by our central pathology review might also be able in 
helping to detect patients who may benefit from tailored salvage RT treatment in terms of RT 
dose and / or additional ADT. 
This analysis has limitations. Even though central pathology review should have been done 
in all patients, due to logistical reasons it was only performed in 80% of patients. As patients 
underwent radical prostatectomy prior to trial enrollment, the prostatectomy specimen were 
processed according to the standards of the local sites. While the determination of rapid 
biochemical progression was based on the first regular follow-up visits, biochemical control 
data has not matured yet and more solid oncological endpoints such as metastasis-free 
survival are not yet available for analysis. 
Conclusion: The results of the central pathology analyses revealed discordant results for 
seminal vesicle invasion, extraprostatic extension, positive surgical margin as well as 
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Gleason score. Largest diameter of carcinoma was found to be a potential prognostic factor 
for rapid biochemical progression after salvage RT. 
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Table 1: Distribution of tumor classification after local vs. central pathological assessment 
 
 
 
  
 
Pathological tumor classification 
(local) 
exact 
concordance
under 
staging  
by LR vs 
CR 
over 
staging 
by LR vs 
CR  
pT2a 
(N=13)
pT2b 
(N=11)
pT2c
(N=140)
pT3a
(N=81)
pT3b
(N=34)
Variable n  n  n n n % % % 
Pathological tumor 
classification (central) 
    
.     pT2a 9  2  0 0 0 81.8% 0.0% 18.2%
.     pT2b 0  2  0 0 0 100.0% 0.0% 0.0%
.     pT2c 1  5  127 7 0 90.7% 4.3% 5.0%
.     pT3a 3  2  13 74 3 77.9% 18.9% 3.2%
.     pT3b 0  0  0 0 31 100.0% 0.0% 0.0%
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Table 2: Distribution of primary and secondary Gleason Pattern and Gleason Score after local vs. 
central pathological assessment 
 
 
 
 
 
 
 
 
 Primary Gleason pattern (local) exact  
concordance
under 
grading  
by LR vs 
CR 
over 
grading 
by LR vs 
CR  
1 
(N=1) 
2 
(N=2) 
3
(N=153)
4
(N=114) 5 
(N=9) 
Variable n n  n n n % % %
Primary Gleason 
pattern (central) 
   
.     3 1 2  128 23 2 82.1% 1.9% 16.0%
.     4 0 0  25 88 2 76.5% 21.7% 1.7%
.     5 0 0  0 3 5 62.5% 37.5% 0.0%
 Secondary Gleason pattern (local)   
 
1 
(N=1) 
2 
(N=3) 
3 
(N=105)
4 
(N=144)
5 
(N=26) 
exact  
concordance
under 
grading  
by LR vs 
CR 
over 
grading 
by LR vs 
CR 
Variable n n  n n n % % %
Secondary Gleason 
pattern (central) 
   
.     3 1 2  71 43 6 57.7% 2.4% 39.8%
.     4 0 1  32 99 8 70.7% 23.6% 5.7%
.     5 0 0  2 2 12 75.0% 25.0% 0.0%
 Gleason score (local)   
 
2 
(N=1) 
5 
(N=4) 
6 
(N=31) 
7 
(N=185)
8 
(N=32) 
9 
(N=26) 
exact  
concordance
under 
grading  
by LR vs 
CR 
over 
grading 
by LR vs 
CR 
Variable n  n n  n n n % % %
Gleason 
score 
(central) 
    
.     6 1  1 20  11 1 0 58.8% 5.9% 35.3%
.     7 0  3 11  170 18 5 82.1% 6.8% 11.1%
.     8 0  0 0  3 11 4 61.1% 16.7% 22.2%
.     9 0  0 0  1 2 17 85.0% 15.0% 0.0%
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 3: Continuous variables of the central pathology review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Variable 
Overall 
(N=279) 
 n median (min, max)
Gleason score (central) 279 7.0 (6.0, 9.0)
Largest diameter of carcinoma (mm) 279 16.0 (3.0, 38.0)
Gleason score of largest cancer lesion 279 7.0 (5.0, 10.0)
Diameter of highest Gleason lesion (mm) 279 15.0 (2.0, 38.0)
Percentage of tumor tissue 279 9.0 (0.5, 66.0)
Size of positive resection margin (mm) 133 2.0 (0.3, 90.0)
Gleason score within positive resection margin 132 7.0 (6.0, 10.0)
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 4: Variables from central pathology review by dichotomized PSA change 
 
 
PSA response or 
stable PSA 
Rapid biochemical 
progression p-value 
Categorical variables Fisher’s 
exact test 
Pathological tumor classification 
(central) 
0.5 
.     pT2a 10 (90.9%) 1 (9.1%)  
.     pT2b 2 (100.0%) 0 (0.0%)  
.     pT2c 116 (84.1%) 22 (15.9%)  
.     pT3a 72 (76.6%) 22 (23.4%)  
.     pT3b 27 (87.1%) 4 (12.9%)  
Perineural invasion 0.009 
.     No 34 (97.1%) 1 (2.9%)  
.     Yes 193 (80.1%) 48 (19.9%)  
Seminal vesical infiltration 0.6 
.     No 199 (81.6%) 45 (18.4%)  
.     Yes 27 (87.1%) 4 (12.9%)  
Lymphovascular invasion 0.3 
.     No 203 (83.2%) 41 (16.8%)  
.     Yes 24 (75.0%) 8 (25.0%)  
Extraprostatic growth 0.3 
.     No 128 (84.8%) 23 (15.1%)  
.     Yes 99 (79.2%) 26 (21.0%)  
Resection margins  0.03 
.     R0 67 (80.7%) 16 (19.3%)  
.     R1 69 (93.2%) 5 (6.8%)  
Continuous variables Wilcoxon 
rank sum 
test 
Gleason score (central) 7.0 (6.0-9.0) 7.0 (6.0-9.0) 0.04 
Gleason score of largest cancer 
lesion 
7.0 (5.0-10.0) 7.0 (6.0-9.0) 0.02 
Largest diameter of carcinoma 
(mm) 
16.0 (3.0-38.0) 18.0 (9.0-35.0) 0.003 
Diameter of highest Gleason 
lesion (mm) 
14.0 (2.0-38.0) 17.0 (2.0-35.0) 0.007 
Percentage of tumor tissue 9.0 (0.5-66.0) 13.0 (1.0-51.0) 0.02 
Size of positive resection margin 
(mm) 
3.0 (0.3-90.0) 1.0 (1.0-20.0) 0.5 
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Table 5: Multivariable regression model for the association of variables of the central pathology 
review and other potentially prognostic variables with dichotomized PSA change 
 
Variable 
Odds Ratio (95% 
CI) 
p-value 
(Wald 
Chi-Square 
test) 
Results of multiple logistic regression (full model)   
     Resection margins (R1 vs R0) 1.64 (1.01-2.65) 0.046 
     Largest diameter of carcinoma (mm)* 0.32 (0.15-0.69) 0.004
     Age at random assignment (years) 1.91 (1.18-3.09) 0.008
     BMI (kg/m2) 1.01 (0.95-1.07) 0.7 
     Lymphadenectomy performed (no [cN0] vs yes [pN0]) 1.01 (0.93-1.10) 0.8 
     Prostatectomy technique (laparoscopic vs robotically assisted) 0.97 (0.32-2.94) 1.0 
     Prostatectomy technique (other vs robotically assisted) 2.30 (0.65-8.07) 0.2 
     Nerve-sparing technique (bilateral vs unilateral) 1.39 (0.53-3.67) 0.5 
     Nerve-sparing technique (none vs unilateral) 0.73 (0.27-1.97) 0.5 
     PSA at randomization (ng/mL) 0.85 (0.35-2.11) 0.7 
     PSA doubling time from prostatectomy to randomization (months) 0.88 (0.25-3.08) 0.8 
Results of multiple logistic regression (after backward selection with 
significance level 0.05) 
  
     Gleason score 1.55 (1.00-2.42) 0.05
     Resection margins (R1 vs R0) 0.36 (0.18-0.72) 0.004
     Largest diameter of carcinoma (mm)* 2.04 (1.30-3.20) 0.002
 
Abbreviations: *IQR-normalized for easier interpretation 
 
 
 
